analysis ABCG2 gene methylation and exporing its effects on pharmacokinetics of rosuvastatin

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-RCH-12002823

Enrollment

Unknown

Registered

2012-12-17

Start date

2013-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

1:rosuvastatin

Eligibility

Sex/Gender

Male

Age

18 Years to 26 Years

Inclusion criteria

Inclusion criteria: SLCO 1B1 521TT, CYP2C9*1/*1, ABCG2 421CC, ABCG2 34GG, gene methylation

Exclusion criteria

Exclusion criteria: SLCO 1B1 521, CYP2C9, ABCG2 421, ABCG2 34 SNPs

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics indexes;	—

Countries

China

Contacts

Public ContactWang Guo

wangguo30@yahoo.com.cn+86 18874878082

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026